Could a simple stress test expose hidden heart risks—long before symptoms appear? New research suggests it might. While many adults diagnosed with hypertrophic cardiomyopathy (HCM) seem healthy and symptom-free, emerging evidence tells a different story. Beneath the surface, silent physiological changes could be putting these patients at long-term risk. And here’s where it gets both fascinating and controversial: treadmill stress echocardiography (TSE), a test often used to gauge heart performance, may hold the key to spotting those dangers before it’s too late.
A major observational study followed over a thousand adults with asymptomatic HCM for nearly 13 years. Each participant, considered symptom-free under the New York Heart Association’s (NYHA) classification, completed resting and stress echocardiograms alongside treadmill testing. Researchers closely measured metabolic equivalents (METs), the age- and sex-adjusted percentage of predicted METs (%AGP-METs), and peak left ventricular outflow tract (LVOT) gradients. The team then tracked outcomes such as all-cause mortality, internal cardioverter-defibrillator (ICD) activations, and heart transplants. These findings, shared at the 2025 American Heart Association (AHA) Scientific Sessions and published in the Journal of the American College of Cardiology, highlight that stress echocardiography does far more than measure fitness—it may predict survival itself.
Hidden Limitations in “Asymptomatic” Patients
Surprisingly, 37% of patients who were labeled as symptom-free could not reach 85% of their predicted exercise capacity. In other words, their hearts told a different story than their medical charts did. Many of these patients also showed signs of obstructive HCM (oHCM), where blood flow from the heart is partially blocked due to increased LVOT gradients—often 30 mm Hg or higher. Those with obstruction typically had thicker heart walls, more leakage through the mitral valve, and achieved lower fitness scores compared to their non-obstructive counterparts (nHCM).
Across an average of nearly 13 years of follow-up, 200 major cardiac events occurred—ranging from death to ICD shocks to transplants. Notably, patients with stronger exercise performance had better long-term survival: 16% event rates for those meeting at least 85% of predicted METs versus 20% for those who did not. And here’s the part most people miss—undergoing a surgical procedure called septal myectomy also changed the equation. Both obstructive and non-obstructive patients who received the surgery had notably fewer major events than those who didn’t (14% versus 23%).
Researchers concluded that even individuals who feel fine might harbor hidden limitations—and that those subtle differences could determine future outcomes. Their takeaway? Every "asymptomatic" HCM patient should be carefully evaluated to confirm their true physiological state and identify potential obstructive patterns early. This could be the difference between proactive treatment and late intervention.
Stress Testing as a Diagnostic Game-Changer
So what makes TSE so powerful? According to the investigators, this test doesn’t just assess endurance—it uncovers hidden strain that resting exams miss. It helps determine whether patients are truly symptom-free or if their bodies are silently compensating for reduced cardiac performance. Previous research has hinted that HCM can progress quietly for years before clinical symptoms ever arise, which makes the new data especially striking.
In the study, TSE proved invaluable in distinguishing degrees of obstruction, revealing dynamic shifts in heart performance under stress, and guiding clinical decisions such as the timing of potential surgical interventions. As the authors put it, the test adds “incremental diagnostic and prognostic value” by clarifying how the heart behaves under real-world conditions.
Of course, not everyone agrees on how widely to apply these findings. Critics note that the study was retrospective and based at a single high-volume center, raising questions about how well the results might apply elsewhere. Still, with its large sample size and long-term data, the research underscores a compelling concept: being symptom-free doesn’t always mean being risk-free.
What do you think? Should treadmill stress echocardiography become a standard part of follow-up for all HCM patients—even those without symptoms? Or are we at risk of overtesting people who might never progress to severe disease? Join the discussion below—because this debate could redefine how we detect and manage hidden heart risks in the future.
